<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-17382" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Allopurinol</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Qurie</surname>
            <given-names>Ahmad</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Preuss</surname>
            <given-names>Charles V.</given-names>
          </name>
          <aff>University of South Florida</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Musa</surname>
            <given-names>Rina</given-names>
          </name>
          <aff>Creighton University School of Medicine</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ahmad Qurie declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Charles Preuss declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Rina Musa declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>26</day>
          <month>6</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-17382.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Allopurinol, a xanthine oxidase inhibitor, is a urate-lowering medication that is FDA approved for managing gout, preventing tumor lysis syndrome, and preventing recurrent calcium nephrolithiasis in patients with hyperuricosuria. Other non-FDA-approved indications include Lesch-Nyhan syndrome-associated hyperuricemia and the prevention of recurrent uric acid nephrolithiasis. It is important to note that asymptomatic hyperuricemia is not an indication of allopurinol or any urate-lowering therapy. This activity outlines the indications, mechanism, pharmacology, contraindications, and adverse events associated with allopurinol drug therapy.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the various indications, both approved and off-label, for allopurinol therapy.</p></list-item><list-item><p>Describe the potential adverse effects of allopurinol.</p></list-item><list-item><p>Summarize the mechanism of action of allopurinol.</p></list-item><list-item><p>Review the importance of coordinating and collaborating among various disciplines in an interprofessional health team to coordinate care and management to enhance outcomes for patients receiving allopurinol therapy.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17382&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17382">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-17382.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Allopurinol, a xanthine oxidase inhibitor, is a urate-lowering medication.</p>
        <p>Allopurinol is FDA approved for the following indications:</p>
        <list list-type="order">
          <list-item>
            <p>Gout</p>
          </list-item>
          <list-item>
            <p>Prevention of tumor lysis syndrome</p>
          </list-item>
          <list-item>
            <p>Prevention of recurrent calcium nephrolithiasis&#x000a0;in patients with hyperuricosuria&#x000a0;</p>
          </list-item>
        </list>
        <p>Other non-FDA-approved&#x000a0;indications include Lesch-Nyhan syndrome-associated hyperuricemia and recurrent uric acid nephrolithiasis prevention.<xref ref-type="bibr" rid="article-17382.r1">[1]</xref></p>
        <p>American College of Rheumatology recommends initiating urate-lowering therapy such as allopurinol&#x000a0;in patients with an established diagnosis of gouty arthritis in the following situations:</p>
        <list list-type="order">
          <list-item>
            <p>Frequent attacks of acute gouty arthritis, defined as equal to or more than two attacks per year</p>
          </list-item>
          <list-item>
            <p>Chronic kidney disease stage 2 or worse</p>
          </list-item>
          <list-item>
            <p>Presence of tophi or tophus on clinical exam or imaging</p>
          </list-item>
          <list-item>
            <p>History of nephrolithiasis</p>
          </list-item>
        </list>
        <p>It is important to note that asymptomatic hyperuricemia is not an indication of allopurinol or any urate-lowering therapy.<xref ref-type="bibr" rid="article-17382.r1">[1]</xref></p>
        <p>Van Liere E. et al. conducted a study on using low-dose azathioprine and allopurinol (LDAA) to treat inflammatory bowel disease. Allopurinol was added to azathioprine to improve its tolerability. The investigators found that LDAA was better tolerated in patients compared with standard azathioprine monotherapy.<xref ref-type="bibr" rid="article-17382.r2">[2]</xref></p>
      </sec>
      <sec id="article-17382.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Allopurinol&#x000a0;undergoes metabolism in the liver, where it transforms into its pharmacologically active metabolite, oxypurinol. The half-life of allopurinol is 1&#x000a0;to 2 hours, and oxypurinol is about 15 hours. Both allopurinol and oxypurinol are renally excreted.&#x000a0;Allopurinol and oxypurinol both inhibit xanthine oxidase, an enzyme in the purine catabolism pathway that converts hypoxanthine to xanthine to uric acid.</p>
        <p>Schmidt A. et al. conducted a clinical trial on the analgesic effects of allopurinol in patients undergoing hysterectomy. The investigators found that allopurinol given as a pre-anesthetic agent reduced pain scores 2 hours after surgery.<xref ref-type="bibr" rid="article-17382.r3">[3]</xref></p>
        <p>Fagundes A. et al. conducted a study (12 women) on allopurinol treatment in patients with fibromyalgia.<xref ref-type="bibr" rid="article-17382.r4">[4]</xref> Allopurinol treatment reduced pain.&#x000a0;However, in a larger study (N = 31 for allopurinol and N = 29 for placebo), allopurinol did not demonstrate analgesic properties in fibromyalgia patients.<xref ref-type="bibr" rid="article-17382.r5">[5]</xref></p>
        <p>Hsu F. et al. found evidence that medium to high doses of allopurinol reduced colorectal cancer risk in patients.<xref ref-type="bibr" rid="article-17382.r6">[6]</xref></p>
        <p>Park S. et al. found that allopurinol was renoprotective in patients with hyperuricemia and chronic kidney disease compared to febuxostat treatment.<xref ref-type="bibr" rid="article-17382.r7">[7]</xref></p>
        <p>Prieto-Moure B. et al. conducted research on small intestine ischemia-reperfusion injury of Wistar rats and the role of allopurinol and dantrolene in preventing oxygen-free radical damage. The researchers found that the allopurinol and dantrolene combination provided antioxidant effects, which decreased the oxygen-free radical damage caused by the ischemia-reperfusion in the rat's small intestines.<xref ref-type="bibr" rid="article-17382.r8">[8]</xref></p>
      </sec>
      <sec id="article-17382.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Allopurinol administration can be in two forms: oral or intravenous (IV). While oral administration is the standard route for gout and uric acid or calcium oxalate nephrolithiasis, IV allopurinol is for the prevention of tumor lysis syndrome and management of cancer therapy-induced hyperuricemia in patients who cannot tolerate oral therapy.</p>
        <p>For long-term gout treatment, the recommended starting dose of allopurinol&#x000a0;is 100 mg daily, to be escalated by 100 mg every 2 to 5 weeks until the target serum uric acid is achieved. American College of Rheumatology recommends target uric acid of less than 6.0 mg/dL for all patients with gout and less than 5.0 mg/dL in patients with tophaceous gout.&#x000a0;The maximum daily allopurinol dose is 800 mg. Following the patient reaching the target serum uric acid concentration, the required dose of allopurinol to achieve the target serum uric acid&#x000a0;concentration should continue indefinitely.<xref ref-type="bibr" rid="article-17382.r1">[1]</xref></p>
        <p>In patients with renal insufficiency (chronic kidney disease stage 4 and greater), allopurinol should start at a 50 mg daily dose, and the dose shall be escalated by 50 mg every 2 to 5 weeks until reaching the target serum uric acid.<xref ref-type="bibr" rid="article-17382.r9">[9]</xref>&#x000a0;Allopurinol and oxypurinol are both dialyzable. In patients with end-stage renal disease on hemodialysis or peritoneal dialysis, allopurinol can be initiated at 50 mg on alternate days and be given post dialysis, with cautious dose escalation to achieve target serum uric acid.</p>
        <p>To prevent tumor lysis syndrome, allopurinol shall be initiated 2 to 3 days before starting chemotherapy and continued until 3 to 7 days after chemotherapy. Doses for&#x000a0;oral allopurinol are 300 mg/m^2/day in&#x000a0;three divided doses every 8 hours, a maximum of 800 mg daily, and IV allopurinol is&#x000a0;200 to 400 mg/m2 daily single doses or 2 to 3 divided doses.</p>
        <p>Allopurinol dosing is 300 mg oral daily for the prevention of recurrent uric acid or calcium nephrolithiasis.</p>
      </sec>
      <sec id="article-17382.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Allopurinol is a relatively safe medication, although adverse effects can occur.</p>
        <p>Due to the destabilization of intra-articular uric acid microtophi on initiating any urate-lowering therapy, there is an increased incidence of acute gouty flares, especially during the initial few months. To prevent this, patients should start an anti-inflammatory agent such as colchicine,&#x000a0;nonsteroidal anti-inflammatory drug (NSAID), or low-dose prednisone (only in patients who cannot take colchicine or NSAIDs) before or at the same time as initiating allopurinol.<xref ref-type="bibr" rid="article-17382.r10">[10]</xref></p>
        <p>Maculopapular pruritic rash, and gastrointestinal adverse effects, including nausea and diarrhea, are other common adverse effects. Laboratory abnormalities can occur, including transaminitis and elevated&#x000a0;serum alkaline phosphatase,&#x000a0;leukopenia, and thrombocytopenia. Other less common and rare adverse effects include&#x000a0;liver necrosis, granulomatous hepatitis, cholestatic jaundice,&#x000a0;interstitial nephritis, and vasculitis.</p>
        <p>Fontana R. et al. conducted research on eleven patients with suspected allopurinol-induced liver damage. The researchers found that hepatoxicity was associated with the following alleles: HLA-B*58:01, HLA-B*53:01, and HLA-A*34:02. The median age was 60 years, 54% were men, and 63% were African-American.<xref ref-type="bibr" rid="article-17382.r11">[11]</xref></p>
        <p>Allopurinol maintenance therapy may increase thyroid-stimulating hormone, which might result from subclinical hypothyroidism.<xref ref-type="bibr" rid="article-17382.r12">[12]</xref></p>
        <p>Allopurinol hypersensitivity syndrome (AHS) is a rare severe adverse effect of allopurinol with an incidence of about 1 in 1000, with a high mortality rate of 20% to 25%. The mechanism is a T-cell-mediated immune reaction to oxypurinol. The highest risk is in the first few months of therapy, especially with higher starting doses of allopurinol. Concurrent diuretics, especially thiazide use, renal insufficiency stage 3, or higher, are major risk factors. Patients of Korean, Han Chinese, and Thai descent with HLA-B*5801 genotype are at a very high risk of AHS. Clinical features of AHS include&#x000a0;Stevens-Johnson syndrome,&#x000a0;toxic epidermal necrolysis, vasculitis, hepatocellular injury, acute kidney injury, fever, leukocytosis, and eosinophilia.<xref ref-type="bibr" rid="article-17382.r13">[13]</xref> Management is supportive. Lowering the starting dose of allopurinol to less than 100 mg daily in all patients and less than 50&#x000a0; mg daily in patients with chronic kidney disease stage 3 or worse can lower the risk of AHS.&#x000a0;Wong C et al. conducted pharmacogenomic testing (HLA-B*58:01 allele) on patients with chronic kidney disease before initiating allopurinol treatment.<xref ref-type="bibr" rid="article-17382.r14">[14]</xref> The pharmacogenomic screening prevents allergic skin reactions, and it is cost-effective.</p>
        <p>Lavu A. et al. reported on a patient with Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN) caused by allopurinol. The patient&#x02019;s clinical presentation gradually resolved with the discontinuation of allopurinol therapy. The patient was found to have the HLA-B*58:01 allele. The investigators recommend pharmacogenomic testing for the HLA-B*58:01 allele before initiating allopurinol therapy to prevent SJS and TEN in susceptible patients.<xref ref-type="bibr" rid="article-17382.r15">[15]</xref></p>
        <p>Several drug interactions exist with allopurinol. The most important drug interaction is with azathioprine and 6-mercaptopurine, both metabolized by the enzyme xanthine oxidase. Using any xanthine oxidase inhibitor such as allopurinol in a patient on azathioprine or 6-mercaptopurine can cause severe agranulocytosis and pancytopenia.</p>
      </sec>
      <sec id="article-17382.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>The presence of the HLA-B*5801 genotype in patients of Korean descent with chronic kidney disease stage 3 or worse, or in patients of Han Chinese or Thai descent irrespective of renal function, is an especially high risk of AHS (hazard ratio of several hundred). American College of Rheumatology recommends screening this population for&#x000a0;HLA-B*5801 genotype using the&#x000a0;polymerase chain reaction (PCR) testing before initiating allopurinol and, if positive, using an alternative urate-lowering therapy. However, universal HLA-B*5801&#x000a0;allopurinol screening is not recommended, given the significantly lower HLA-B*5801 prevalence and hazard ratio in other populations.</p>
      </sec>
      <sec id="article-17382.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Complete blood count, liver function tests, renal function, and serum uric acid levels shall be measured&#x000a0;every 2 to 5 weeks while titrating the dose until achieving the target serum uric acid level and every six months thereafter. Patients need counseling about the signs and symptoms of AHS with a recommendation to discontinue allopurinol promptly if they develop skin rash concerning AHS, especially early in therapy.&#x000a0;</p>
        <p>The manufacturer recommends that patients on allopurinol discontinue the drug for one week before breastfeeding. However, the mother could continue allopurinol therapy in exclusively breastfed babies with careful monitoring of the child for allergic reactions and complete blood counts.<xref ref-type="bibr" rid="article-17382.r16">[16]</xref></p>
      </sec>
      <sec id="article-17382.s8" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Allopurinol is a relatively safe drug that has been used for over half a century. Still, recent studies in gout have shown significant underutilization of this agent and suboptimal dose use, insufficient to reach target serum uric acid&#x000a0;concentrations in a considerable proportion of gout patients. A problem with allopurinol treatment for gout is therapy adherence. Emad Y. et al. found that the most common reason for lack of patient adherence to pharmacotherapy is: "patients wanting to lead a normal life."<xref ref-type="bibr" rid="article-17382.r17">[17]</xref> This is an opportunity for healthcare professionals to improve pharmacotherapy adherence.</p>
        <p>Contrary to the common belief, recent studies have shown that allopurinol is safe in severe chronic kidney disease and can impede the progression of renal disease in patients with gout and chronic kidney disease.<xref ref-type="bibr" rid="article-17382.r18">[18]</xref><xref ref-type="bibr" rid="article-17382.r19">[19]</xref>&#x000a0;Using allopurinol in patients with gout is also associated with lower all-cause mortality and other adverse cardiovascular events, including readmissions due to congestive heart failure.<xref ref-type="bibr" rid="article-17382.r19">[19]</xref><xref ref-type="bibr" rid="article-17382.r20">[20]</xref><xref ref-type="bibr" rid="article-17382.r21">[21]</xref><xref ref-type="bibr" rid="article-17382.r22">[22]</xref>&#x000a0;American College of Rheumatology recommends allopurinol as one of the first-line agents of urate-lowering therapy for gout management.&#x000a0;Several studies report that allopurinol reduced cardiovascular events. However, research by Suissa S. et al. concludes that these studies contained time-related biases and, thus, allopurinol does not provide cardiovascular protection.<xref ref-type="bibr" rid="article-17382.r23">[23]</xref></p>
        <p>There are, however, potential rare though severe adverse effects associated with allopurinol. The use of allopurinol&#x000a0;requires management by an interprofessional healthcare team that includes clinicians (MDs, DOs, NPs, PAs), nurses, and pharmacists. Clinicians initiating allopurinol therapy should ensure no drug interactions and that xanthine oxidase inhibitor therapy is the optimal choice; if necessary, a pharmacist consult can assist in this evaluation. Pharmacists can also verify dosing and provide additional patient counsel regarding how to take the drug. The nursing team shall assist with verifying patient&#x000a0;adherence and helping to monitor for adverse events and therapeutic effectiveness. All team members should document their observations in the patient's permanent health record, and be prepared to reach out to other team members when necessary, so alterations to the therapeutic regimen can be made. The best chance for allopurinol to have therapeutic success with minimal adverse events is via an interprofessional team approach. [Level 5]</p>
      </sec>
      <sec id="article-17382.s9">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17382&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17382">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/17382/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=17382">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-17382.s10">
        <title>References</title>
        <ref id="article-17382.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khanna</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Fitzgerald</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Khanna</surname>
                <given-names>PP</given-names>
              </name>
              <name>
                <surname>Bae</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Neogi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Pillinger</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Merill</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Prakash</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kaldas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gogia</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Perez-Ruiz</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Liot&#x000e9;</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Dalbeth</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kaplan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Niyyar</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Yarows</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Roessler</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kerr</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>King</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Furst</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Edwards</surname>
                <given-names>NL</given-names>
              </name>
              <name>
                <surname>Mandell</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Schumacher</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Robbins</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wenger</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Terkeltaub</surname>
                <given-names>R</given-names>
              </name>
              <collab>American College of Rheumatology</collab>
            </person-group>
            <article-title>2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia.</article-title>
            <source>Arthritis Care Res (Hoboken)</source>
            <year>2012</year>
            <month>Oct</month>
            <volume>64</volume>
            <issue>10</issue>
            <fpage>1431</fpage>
            <page-range>1431-46</page-range>
            <pub-id pub-id-type="pmid">23024028</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17382.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van Liere</surname>
                <given-names>ELSA</given-names>
              </name>
              <name>
                <surname>Bayoumy</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Mulder</surname>
                <given-names>CJJ</given-names>
              </name>
              <name>
                <surname>Warner</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Hayee</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Mateen</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Nolan</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>de Boer</surname>
                <given-names>NKH</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>SHC</given-names>
              </name>
              <name>
                <surname>Ansari</surname>
                <given-names>AR</given-names>
              </name>
            </person-group>
            <article-title>Azathioprine with Allopurinol Is a Promising First-Line Therapy for Inflammatory Bowel Diseases.</article-title>
            <source>Dig Dis Sci</source>
            <year>2022</year>
            <month>Aug</month>
            <volume>67</volume>
            <issue>8</issue>
            <fpage>4008</fpage>
            <page-range>4008-4019</page-range>
            <pub-id pub-id-type="pmid">34729677</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17382.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schmidt</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>de Oliveira</surname>
                <given-names>ED</given-names>
              </name>
              <name>
                <surname>Fagundes</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Hansel</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Pedrini</surname>
                <given-names>RO</given-names>
              </name>
              <name>
                <surname>Valdameri</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Martinelli</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Schmidt</surname>
                <given-names>SRG</given-names>
              </name>
              <name>
                <surname>Andrade</surname>
                <given-names>CF</given-names>
              </name>
              <name>
                <surname>Lara</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Souza</surname>
                <given-names>DO</given-names>
              </name>
            </person-group>
            <article-title>Allopurinol attenuates postoperative pain and modulates the purinergic system in patients undergoing abdominal hysterectomy: a randomized controlled trial.</article-title>
            <source>J Anesth</source>
            <year>2021</year>
            <month>Dec</month>
            <volume>35</volume>
            <issue>6</issue>
            <fpage>818</fpage>
            <page-range>818-826</page-range>
            <pub-id pub-id-type="pmid">34390392</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17382.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fagundes</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Souza</surname>
                <given-names>DO</given-names>
              </name>
              <name>
                <surname>Schmidt</surname>
                <given-names>AP</given-names>
              </name>
            </person-group>
            <article-title>Effects of allopurinol on pain and anxiety in fibromyalgia patients: a pilot study.</article-title>
            <source>Braz J Anesthesiol</source>
            <year>2021</year>
            <season>Nov-Dec</season>
            <volume>71</volume>
            <issue>6</issue>
            <fpage>660</fpage>
            <page-range>660-663</page-range>
            <pub-id pub-id-type="pmid">34715996</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17382.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fagundes</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>de Oliveira</surname>
                <given-names>ED</given-names>
              </name>
              <name>
                <surname>Ferrari</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Dos Santos</surname>
                <given-names>LMM</given-names>
              </name>
              <name>
                <surname>Botelho</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Schmidt</surname>
                <given-names>SRG</given-names>
              </name>
              <name>
                <surname>Andrade</surname>
                <given-names>CF</given-names>
              </name>
              <name>
                <surname>Lara</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Souza</surname>
                <given-names>DO</given-names>
              </name>
              <name>
                <surname>Schmidt</surname>
                <given-names>AP</given-names>
              </name>
            </person-group>
            <article-title>Allopurinol for fibromyalgia pain in adults: A randomized controlled trial.</article-title>
            <source>Pain Pract</source>
            <year>2022</year>
            <month>Jan</month>
            <volume>22</volume>
            <issue>1</issue>
            <fpage>19</fpage>
            <page-range>19-27</page-range>
            <pub-id pub-id-type="pmid">33864725</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17382.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hsu</surname>
                <given-names>FG</given-names>
              </name>
              <name>
                <surname>Lai</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>CY</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Hsieh</surname>
                <given-names>YW</given-names>
              </name>
            </person-group>
            <article-title>Exploring the Relationship Between Colorectal Cancer and Allopurinol: A Taiwanese Population-Based Propensity-Matched Case-Control Study.</article-title>
            <source>J Clin Pharmacol</source>
            <year>2021</year>
            <month>Aug</month>
            <volume>61</volume>
            <issue>8</issue>
            <fpage>1131</fpage>
            <page-range>1131-1137</page-range>
            <pub-id pub-id-type="pmid">33580545</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17382.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Park</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>YS</given-names>
              </name>
              <name>
                <surname>Lim</surname>
                <given-names>CS</given-names>
              </name>
            </person-group>
            <article-title>Superior effect of allopurinol compared to febuxostat on the retardation of chronic kidney disease progression.</article-title>
            <source>PLoS One</source>
            <year>2022</year>
            <volume>17</volume>
            <issue>2</issue>
            <fpage>e0264627</fpage>
            <pub-id pub-id-type="pmid">35226683</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17382.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Prieto-Moure</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Cejalvo-Lape&#x000f1;a</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Belda-Antol&#x000ed;</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Padr&#x000f3;n-Sanz</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lloris-Cejalvo</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Lloris-Cars&#x000ed;</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Combination Therapy of Allopurinol and Dantrolene and Its Role In The Prevention of Experimental Ischemia Reperfusion Injury Of The Small Intestine.</article-title>
            <source>J Invest Surg</source>
            <year>2021</year>
            <month>Jul</month>
            <volume>34</volume>
            <issue>7</issue>
            <fpage>800</fpage>
            <page-range>800-807</page-range>
            <pub-id pub-id-type="pmid">31906750</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17382.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stamp</surname>
                <given-names>LK</given-names>
              </name>
              <name>
                <surname>O'Donnell</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>James</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Frampton</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Barclay</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Chapman</surname>
                <given-names>PT</given-names>
              </name>
            </person-group>
            <article-title>Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment.</article-title>
            <source>Arthritis Rheum</source>
            <year>2011</year>
            <month>Feb</month>
            <volume>63</volume>
            <issue>2</issue>
            <fpage>412</fpage>
            <page-range>412-21</page-range>
            <pub-id pub-id-type="pmid">21279998</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17382.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khanna</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Khanna</surname>
                <given-names>PP</given-names>
              </name>
              <name>
                <surname>Fitzgerald</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Bae</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Neogi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Pillinger</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Merill</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Prakash</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kaldas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gogia</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Perez-Ruiz</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Liot&#x000e9;</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Dalbeth</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kaplan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Niyyar</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Yarows</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Roessler</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kerr</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>King</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Furst</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Edwards</surname>
                <given-names>NL</given-names>
              </name>
              <name>
                <surname>Mandell</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Schumacher</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Robbins</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wenger</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Terkeltaub</surname>
                <given-names>R</given-names>
              </name>
              <collab>American College of Rheumatology</collab>
            </person-group>
            <article-title>2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis.</article-title>
            <source>Arthritis Care Res (Hoboken)</source>
            <year>2012</year>
            <month>Oct</month>
            <volume>64</volume>
            <issue>10</issue>
            <fpage>1447</fpage>
            <page-range>1447-61</page-range>
            <pub-id pub-id-type="pmid">23024029</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17382.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fontana</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>YJ</given-names>
              </name>
              <name>
                <surname>Phillips</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Saeed</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Barnhart</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kleiner</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hoofnagle</surname>
                <given-names>J</given-names>
              </name>
              <collab>Drug Induced Liver Injury Network</collab>
            </person-group>
            <article-title>Allopurinol hepatotoxicity is associated with human leukocyte antigen Class I alleles.</article-title>
            <source>Liver Int</source>
            <year>2021</year>
            <month>Aug</month>
            <volume>41</volume>
            <issue>8</issue>
            <fpage>1884</fpage>
            <page-range>1884-1893</page-range>
            <pub-id pub-id-type="pmid">33899326</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17382.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Choi</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>YS</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>YW</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ko</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Yoo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Oh</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Kang</surname>
                <given-names>DY</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>IY</given-names>
              </name>
            </person-group>
            <article-title>Association between the use of allopurinol and risk of increased thyroid-stimulating hormone level.</article-title>
            <source>Sci Rep</source>
            <year>2021</year>
            <month>Oct</month>
            <day>13</day>
            <volume>11</volume>
            <issue>1</issue>
            <fpage>20305</fpage>
            <pub-id pub-id-type="pmid">34645831</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17382.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hoyer</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Atti</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Nuding</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Vogt</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sedding</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Schott</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Toxic Epidermal Necrolysis Caused by Allopurinol: A Serious but Still Underestimated Adverse Reaction.</article-title>
            <source>Am J Case Rep</source>
            <year>2021</year>
            <month>Oct</month>
            <day>11</day>
            <volume>22</volume>
            <fpage>e932921</fpage>
            <pub-id pub-id-type="pmid">34634004</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17382.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wong</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Yeung</surname>
                <given-names>CK</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>CY</given-names>
              </name>
              <name>
                <surname>Yap</surname>
                <given-names>DY</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Cheung</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Kwok</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>HH</given-names>
              </name>
            </person-group>
            <article-title>HLA-B*58:01 screening to prevent allopurinol-induced severe cutaneous adverse reactions in Chinese patients with chronic kidney disease.</article-title>
            <source>Arch Dermatol Res</source>
            <year>2022</year>
            <month>Sep</month>
            <volume>314</volume>
            <issue>7</issue>
            <fpage>651</fpage>
            <page-range>651-659</page-range>
            <pub-id pub-id-type="pmid">34213582</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17382.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lavu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Thiriveedi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Khera</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Saravu</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Rao</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Clinical Utility of <italic>HLA-B*58:01</italic> Genotyping to Prevent Allopurinol-Induced SJS/TEN.</article-title>
            <source>Hosp Pharm</source>
            <year>2021</year>
            <month>Dec</month>
            <volume>56</volume>
            <issue>6</issue>
            <fpage>660</fpage>
            <page-range>660-663</page-range>
            <pub-id pub-id-type="pmid">34732918</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17382.r16">
          <label>16</label>
          <element-citation publication-type="book">
            <chapter-title>Allopurinol</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2022</year>
            <month>3</month>
            <day>21</day>
            <pub-id pub-id-type="pmid">30000257</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17382.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Emad</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Dalbeth</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Weinman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chalder</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Petrie</surname>
                <given-names>KJ</given-names>
              </name>
            </person-group>
            <article-title>Why Do Patients With Gout Not Take Allopurinol?</article-title>
            <source>J Rheumatol</source>
            <year>2022</year>
            <month>Jun</month>
            <volume>49</volume>
            <issue>6</issue>
            <fpage>622</fpage>
            <page-range>622-626</page-range>
            <pub-id pub-id-type="pmid">35169055</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17382.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Siu</surname>
                <given-names>YP</given-names>
              </name>
              <name>
                <surname>Leung</surname>
                <given-names>KT</given-names>
              </name>
              <name>
                <surname>Tong</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Kwan</surname>
                <given-names>TH</given-names>
              </name>
            </person-group>
            <article-title>Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level.</article-title>
            <source>Am J Kidney Dis</source>
            <year>2006</year>
            <month>Jan</month>
            <volume>47</volume>
            <issue>1</issue>
            <fpage>51</fpage>
            <page-range>51-9</page-range>
            <pub-id pub-id-type="pmid">16377385</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17382.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goicoechea</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Garcia de Vinuesa</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Verdalles</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Verde</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Macias</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Santos</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>P&#x000e9;rez de Jose</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cede&#x000f1;o</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Linares</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Lu&#x000f1;o</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Allopurinol and progression of CKD and cardiovascular events: long-term follow-up of a randomized clinical trial.</article-title>
            <source>Am J Kidney Dis</source>
            <year>2015</year>
            <month>Apr</month>
            <volume>65</volume>
            <issue>4</issue>
            <fpage>543</fpage>
            <page-range>543-9</page-range>
            <pub-id pub-id-type="pmid">25595565</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17382.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Luk</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Levin</surname>
                <given-names>GP</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>EE</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>XH</given-names>
              </name>
              <name>
                <surname>Kestenbaum</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>HK</given-names>
              </name>
            </person-group>
            <article-title>Allopurinol and mortality in hyperuricaemic patients.</article-title>
            <source>Rheumatology (Oxford)</source>
            <year>2009</year>
            <month>Jul</month>
            <volume>48</volume>
            <issue>7</issue>
            <fpage>804</fpage>
            <page-range>804-6</page-range>
            <pub-id pub-id-type="pmid">19447769</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17382.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thanassoulis</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Brophy</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Richard</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Pilote</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Gout, allopurinol use, and heart failure outcomes.</article-title>
            <source>Arch Intern Med</source>
            <year>2010</year>
            <month>Aug</month>
            <day>09</day>
            <volume>170</volume>
            <issue>15</issue>
            <fpage>1358</fpage>
            <page-range>1358-64</page-range>
            <pub-id pub-id-type="pmid">20696962</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17382.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Struthers</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Donnan</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Lindsay</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>McNaughton</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Broomhall</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>MacDonald</surname>
                <given-names>TM</given-names>
              </name>
            </person-group>
            <article-title>Effect of allopurinol on mortality and hospitalisations in chronic heart failure: a retrospective cohort study.</article-title>
            <source>Heart</source>
            <year>2002</year>
            <month>Mar</month>
            <volume>87</volume>
            <issue>3</issue>
            <fpage>229</fpage>
            <page-range>229-34</page-range>
            <pub-id pub-id-type="pmid">11847159</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17382.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Suissa</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Suissa</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hudson</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Allopurinol and Cardiovascular Events: Time-Related Biases in Observational Studies.</article-title>
            <source>Arthritis Care Res (Hoboken)</source>
            <year>2022</year>
            <month>May</month>
            <volume>74</volume>
            <issue>5</issue>
            <fpage>858</fpage>
            <page-range>858-865</page-range>
            <pub-id pub-id-type="pmid">34057310</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
